Glaukos Corporation (NASDAQ:GKOS) is an innovative medical technology company known for pioneering the development of Micro-Invasive Glaucoma Surgery (MIGS) devices. The company’s lead product line is the iStent, a revolutionary device used in conjunction with cataract surgery to dramatically reduce intraocular pressure (IOP) in adult mild-to-moderate open-angle glaucoma patients.
Founded in 1998 and based in San Clemente, California, Glaukos is dedicated to developing micro-scale technologies to address significant unmet clinical needs in glaucoma treatment. The company is driven by a deep sense of responsibility to find new solutions that can transform patients’ lives by changing the way this debilitating disease is treated.
Glaukos' iStent is the smallest medical device ever approved by FDA and is backed by a plethora of clinical studies. It works by providing a permanent pathway for fluid to flow out of the eye, thereby reducing the pressure inside the eye which causes glaucoma. In addition, Glaukos is also known for other innovative MIGS devices including the iStent Supra and iStent inject.
Beyond MIGS, Glaukos is investing in R&D and pipeline expansion to develop strategies for other ocular diseases, such as age-related macular degeneration and refractive correction. One of the most promising pipelines is the iDose Travoprost, an implantable drug delivery device for the continuous release of medication inside the eye, reducing the burden of topical glaucoma medication administration for the patients.
Glaukos has been publicly traded on the New York Stock Exchange since 2015 under the ticker symbol “GKOS”. Today, the company is a recognized global leader in glaucoma care, with products sold in more than 25 countries. Despite dynamic market competition, Glaukos remains ahead of the curve thanks to its robust pipeline and laser-focused commitment to innovation.
In conclusion, Glaukos Corporation is a pioneer in the field of ophthalmology, producing ground-breaking products and delivering exceptional patient outcomes. The company's unyielding commitment to improving and advancing glaucoma treatment has led to significant industry growth and continues to generate excitement for future innovations.